(Sharecast News) - Shield Therapeutics said on Monday that the US Food and Drug Administration (FDA) has approved an extension of the indication for its iron deficiency treatment Accrufer to include paediatric patients aged 10 years and older, following a priority review.
The AIM-traded pharmaceutical company said Accrufer, which contains ferric...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE